1. Date of shareholders' resolution: 115/05/22. 2. Permitted directors: Li Fang-chuan (Corporate Rep), Chien Chih-wei (Corporate Rep), Luo Bao-zhu (Independent Director). 3. Permitted behavior: Investing in or managing companies with similar business scope. 4. Mainland China business: Li Fang-chuan holds positions at Dequan Pharmaceutical (Jiangsu) and Dezhen Medicine (Jiangsu). 5. Financial impact: No material impact.

FACT BOX

  • Source: PR Times
  • Category: corporate_governance
  • Dates in source: 115/05/22